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Abstract
BACKGROUND 
Primary extra-gastrointestinal stromal tumors (E-GIST) of the liver are rare. The 
clinical presentation may range from asymptomatic to bleeding or manifestations 
of mass effect. Oncologic surgery followed by adjuvant therapy with imatinib is 
the standard of care. However, under specific circumstances, a cytoreductive 
approach may represent a therapeutic option. We describe herein the case of an 
84-year-old woman who presented with a tender, protruding epigastric mass. 
Abdominal computed tomography scan revealed a large, heterogeneous mass 
located across segments III, IV, V, and VIII of the liver. The initial approach was 
transarterial embolization of the tumor, which elicited no appreciable response. 
Considering the large size and central location of the tumor and the advanced age 
of the patient, non-anatomic complete resection was indicated. Due to substantial 
intraoperative bleeding and hemodynamic instability, only a near-complete 
resection could be achieved. Histopathology and immunohistochemical staining 
confirmed the diagnosis of primary E-GIST of the liver. Considering the 
risk/benefit ratio for therapeutic options, debulking surgery may represent a 
strategy to control pain and prolong survival.
Fernandes MR et al. Primary E-GIST of the liver
WJGS https://www.wjgnet.com 316 March 27, 2021 Volume 13 Issue 3
Grande do Sul.
Informed consent statement: 
Informed written consent was 
obtained from the patient for 
publication of this report and any 
accompanying images.
Conflict-of-interest statement: The 
authors declare that they have no 
conflict of interest.
CARE Checklist (2016) statement: 
The authors have read the CARE 
Checklist (2016), and the 
manuscript was prepared and 
revised according to the CARE 
Checklist (2016).
Open-Access: This article is an 
open-access article that was 
selected by an in-house editor and 
fully peer-reviewed by external 
reviewers. It is distributed in 
accordance with the Creative 
Commons Attribution 
NonCommercial (CC BY-NC 4.0) 
license, which permits others to 
distribute, remix, adapt, build 
upon this work non-commercially, 
and license their derivative works 
on different terms, provided the 
original work is properly cited and 
the use is non-commercial. See: htt
p://creativecommons.org/License
s/by-nc/4.0/
Manuscript source: Unsolicited 
manuscript
Specialty type: Gastroenterology 
and hepatology
Country/Territory of origin: Brazil
Peer-review report’s scientific 
quality classification
Grade A (Excellent): 0 
Grade B (Very good): 0 
Grade C (Good): C, C 
Grade D (Fair): 0 
Grade E (Poor): 0
Received: October 3, 2020 
Peer-review started: October 3, 
2020 
First decision: December 4, 2020 
Revised: December 17, 2020 
Accepted: March 7, 2021 
Article in press: March 7, 2021 
Published online: March 27, 2021
P-Reviewer: Kohno S 
CASE SUMMARY 
Here, we present a case report of a patient diagnosed with E-GIST primary of the 
liver, which was indicated a cytoreductive surgery and adjuvant therapy with 
imatinib.
CONCLUSION 
E-GIST primary of the liver is a rare conditional, the treatment is with systemic 
therapy and total resection surgery. However, a cytoreductive surgery will be 
necessary when a complete resection is no possible.
Key Words: Extra-gastrointestinal stromal tumor; Primary gastrointestinal stromal tumor of 
the liver; Cytoreductive surgery; Debulking surgery; Case report
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: Extra-gastrointestinal stromal tumor (E-GIST) of the liver is a rare condition, 
but the clinical presentation and treatment is similar to GIST of digestive tract. We 
present herein a case of giant hepatic E-GIST in an oldest person already reported and 
treated by cytoreductive surgery. This case highlights because it contributes to 
discussion of treatment approach, such as, the management of large hepatic masses, 
especially in GIST, and patient who would not tolerate major surgical resections.
Citation: Fernandes MR, Ghezzi CLA, Grezzana-Filho TJ, Feier FH, Leipnitz I, Chedid AD, 
Cerski CTS, Chedid MF, Kruel CRP. Giant hepatic extra-gastrointestinal stromal tumor treated 
with cytoreductive surgery and adjuvant systemic therapy: A case report and review of 




Gastrointestinal (GI) stromal tumors (GISTs) arise from the interstitial cells of Cajal, 
located in the GI mesenchyme[1,2]. However, GISTs have also been also encountered in 
other sites that lack these cells, including the mesentery, omentum, and abdominal 
wall, suggesting that pluripotent mesenchymal stem cells are responsible for the 
development of GISTs outside the GI tract[3]. GISTs are currently classified according to 
histopathological and immunohistochemical criteria, based on expression of the 
tyrosine kinase KIT (CD117, c-Kit) by tumor cells[4,5]. GISTs located outside the GI tract 
are appropriately known as extra-GIST (E-GIST), and represent 1% of all GISTs[6,7]. 




An 84-year-old woman, Caucasian, was admitted to our hospital with persistent upper 
abdominal pain.
History of present illness
An 84-year-old woman, Caucasian, was admitted to our hospital with 3-mo history 
right hypochondrium and epigastric pain. There was no history of fever, jaundice, 
coluria and acholia or unintentional weight loss.
History of past illness
The patient had no history of hepatic or GI diseases, malignancy, or previous 
surgeries.
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Physical examination revealed a painful, protruding epigastric mass.
Laboratory examinations
Liver function tests were within normal range, hemogram (hemoglobin 7.2 and 
hematocrit 24.7) and hepatitis B, hepatitis C, and human immunodeficiency virus 
serology were negative. Ca 19-9 levels were elevated (220 U/mL), while serum α-
fetoprotein, CA-125, and carcinoembryonic antigen were within normal limits
Imaging examinations
A GI workup including endoscopy and colonoscopy did not show any significant 
abnormality.
Computed tomography (CT) scan of the abdomen demonstrated a large (18.0 cm × 
16.1 cm × 14.7 cm), heterogeneous hepatic mass, located in segments III, IV, V and VIII, 
with a solid peripheral component showing intense arterial enhancement and late-
phase washout (Figure 1). Magnetic resonance imaging showed evidence of blood 
products within the liver mass. Dilation of the intra-hepatic bile ducts around the 
lesion was also observed (Figure 2).
MULTIDISCIPLINARY EXPERT CONSULTATION
A percutaneous tumor biopsy was performed. Histopathological analysis suggested an 
undifferentiated malignancy. Immunohistochemistry revealed liver cells with low 
mitotic index (10%). Thus, findings on imaging exams suggesting expansive tumor, 
well delimited and with preservation of vascular e biliary structures, despite the 
inconclusive biopsy, the hypothesis of GIST was considered. Pre-operative evaluation 
was performed according our protocol which was adapted from ACC/AHA Guideline 
on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing 
Noncardiac Surgery.
FINAL DIAGNOSIS
Histopathological analysis of the tumor showed a fusiform cell neoplasm positive for 
CD117, CD34 and DOG-1 and negative for spinal muscular atrophy and S-100 protein 
on immunohistochemical staining. The specimen presented a Ki67 index of 10%, 
which confirmed the diagnosis of primary E-GIST of the liver with intermediate-grade 
malignancy (Figure 3).
TREATMENT
As the patient presented with progressive anemia and the lesion had a hemorrhagic 
component, the decision was made to perform transarterial embolization (TAE) of the 
tumor. There was no appreciable response, as well as mass effects symptoms were 
present, surgery was indicated. However, for complete resection of the tumor a left 
trissegmentectomy would be necessary. Considering the large size and central location 
of the lesion and advanced age of the patient, a non-anatomic complete resection was 
indicated. Ligation of the left hepatic artery was carried out. During tumor 
enucleation, the patient developed considerable bleeding and hemodynamic 
instability. Thus, a near-complete resection was performed (the posterior tumor 
capsule close to the raw surface of the liver was not removed) (Figure 4).
OUTCOME AND FOLLOW-UP
Postoperative follow-up was uneventful. After 6 mo, she remains asymptomatic and 
with no evidence of recurrent disease. An abdominal CT performed 6 mo after surgery 
demonstrated significant debulking of the mass (Figure 5).
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Figure 1 Abdominal computed tomography showing an expansive hepatic mass with a solid component (arrows). A: Intense arterial 
enhancement; B: Late-phase washout were present.
Figure 2 Magnetic resonance imaging showing a large, central, T1-hyperintense hepatic lesion. A: Blood products (asterisk); B: Arterial 
enhancement of the solid component (arrow); C: Magnetic resonance cholangiogram showing dilation of the intrahepatic bile ducts.
DISCUSSION
GISTs are the most common mesenchymal neoplasm of the GI tract, representing 
0.1%-0.3% of all malignancies; they are typically found in the stomach (60%-70%), 
small intestine (20%-30%), colorectum (5%), and esophagus (< 2%)[4,8-10]. However, 
GISTs have been identified outside of the GI tract (E-GISTs)[6,7]. Primary hepatic E-
GISTs are very unusual, with only 22 cases reported in the literature up to 2019[1,5,11-29] 
(Table 1). No previous reports of cytoreductive surgery for primary E-GIST of the liver 
were found.
GISTs presenting in the liver are usually metastatic until proven otherwise. There is 
no specific test able to define their primary or metastatic nature, and the diagnosis of 
primary hepatic E-GIST has to fulfill several conditions[15]. Endoscopic and imaging 
studies must show no evidence of GIST in the GI tract, absence of connection with the 
muscularis propria of the GI tract must be proven, and the patient must have no 
medical history suggesting resection of an overlooked or misdiagnosed GIST[3]. 
Diagnosis of a new GI tumor during the follow-up period also would preclude 
diagnosis of a primary GIST of the liver[15]. The patient reported in this paper has 
completed 6 mo of follow-up after surgery and, so far, all the aforementioned 
requirements for diagnosis of a primary hepatic E-GIST have been fulfilled.
The imaging picture of a primary E-GIST of the liver is a well-defined, 
heterogeneous, hypervascular lesion with areas of hemorrhage, necrosis, and/or cystic 
degeneration[30,31]. Thus, primary hepatic E-GISTs can be potentially misdiagnosed as 
other hepatic tumors, such as hypervascular metastasis, hepatocellular carcinoma and 
adenoma. Despite their rarity, primary hepatic E-GIST should be included in the 
differential diagnosis of primary liver lesions whenever a heterogeneous 
hypervascular liver mass is identified, especially in patients with no known primary 
neoplasia, no history of chronic liver disease, and no risk factors for adenoma[20].
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Table 1 Clinical characteristics and location in selected patients with extra-gastrointestinal stromal tumor of the liver
Ref. Year Age/sex Country Presentation Location Size (cm)
Present 2020 84/F Brazil Abdominal pain + mass Bilobar (III/IV and V/VIII) 16.2
Hu et al[14] 2019 79/F China Epigastric discomfort RL 3.2
Joyon et al[15] 2018 56/M France Abdominal pain Bilobar (VII/VIII and LL) 10
2018 59/F France Abdominal pain + weight loss RL 23
Carrillo et at[12] 2017 41/M Spain Abdominal pain + weight loss RL (V/VI) 20
Lok et al[19] 2017 50/F China Abdominal pain RL 15
Cheng et al[13] 2016 63/M China No symptoms RL 15
Nagai et al[28] 2016 70/F Japan No symptoms LL 6
Wang et al[29] 2016 61/M China No symptoms Caudate lobe 7.3
Liu et al[18] 2016 56/F China No symptoms LL + pancreas 2.2
Su et al[24] 2015 65/M Taiwan Malaise, abdominal pain, loss of appetite LL 12
Bhoy et al[11] 2014 41/F India Abdominal pain, weight loss RL (VI/VII) 15
Lin et al[17] 2015 67/F China No symptoms RL 7.4
Mao et al[22] 2015 60/F China No symptoms Bilobar (I, IV, V and VIII) 12.8
Kim et al[16] 2014 71/M South Korea No symptoms LL 7
Louis et al[20] 2014 55/F India Abdominal pain, loss of appetite Bilobar (II, III, VI and VIII) 14.5
Zhou et al[27] 2014 56/M China No symptoms RL 10
Li et al[37] 2012 53/M China Abdominal discomfort RL 20
Yamamoto et al[25] 2010 70/M Japan Loss of appetite LL 20
Luo et al[21] 2009 17/M China No symptoms RL 5
Ochiai et al[23] 2009 30/M Japan Abdominal fullness Bilobar 27
De Chiara et al[5] 2006 37/M Italy No symptoms RL (V) 18
Hu et al[1] 2003 79/F United States Shortness of breath, pleuritic chest pain RL 15
M: Male; F: Female; RL: Right lobe; LL: Left lobe.
Complete surgical resection followed by adjuvant therapy with imatinib is the 
standard of care for localized GIST, but other therapeutic options have been proposed, 
depending on the initial presentation and clinical context. Cytoreductive surgery has 
been used to prolong survival and improve quality of life for patients with metastatic 
neuroendocrine and ovarian cancer[32,33]. However, there is a scarcity of studies 
analyzing the impact of alternative treatments for advanced GIST, especially those 
cases in which complete R0 resection cannot be achieved. Recently, it has been 
demonstrated that debulking surgery combined with adjuvant drug therapy prolongs 
overall survival of patients with metastatic primary GIST when compared with 
imatinib alone[34]. TAE is also recommended as an option to impair stromal tumor 
progression[35].
In this case, a giant hepatic GIST was observed in a very frail 84-year-old woman. 
TAE was indicated to reduce tumor burden, an anatomic liver resection was avoided, 
and a tailored therapeutic approach was recommended. Despite the hypervascular 
nature of the tumor, there was no significant shrinkage after TAE. It was unlikely that 
pain and symptomatic relief would be achieved by systemic therapy alone, which also 
has been associated with GI and/or intra-abdominal bleeding due to tumor 
degeneration in approximately 5% of giant GISTs[36]. Therefore, considering the 
risk/benefit ratio, tumor debulking surgery was indicated as a strategy to control pain 
and improve patient quality of life while avoiding the morbidity and mortality 
associated with a major liver resection. Six months after adjuvant therapy with 
imatinib, she is asymptomatic with little residual tumor, as shown in the last 
abdominal CT scan (Figure 5).
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Figure 3 Histopathological examination. A: bundles of spindle-shaped cells in an irregular pattern, eosinophilic cytoplasm, with normal hepatic parenchyma in 
peripheral areas in hematoxylin-eosin staining (magnification, × 100); B-D: Immunohistochemical analysis showed that the tumor was positive for Ki-67 (B), CD-117 
(C) and DOG1 (D) (magnification, × 100).
Figure 4 Area of tumor resection. Arrows show the residual tumor capsule.
CONCLUSION
E-GIST must be considered in the differential diagnosis of any large, hypervascular 
liver mass. Preoperative histopathological and immunohistochemical diagnosis is 
important to aid in therapeutic management. Aggressive strategies such as R0 surgical 
resection should always be the first choice, but a customized approach including a 
combination of TAE, cytoreductive surgery, and adjuvant or neoadjuvant systemic 
pharmacotherapy might be considered as an alternative, especially in high-risk 
patients.
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Figure 5 Follow-up abdominal computed tomography scan showing significant reduction of the hepatic mass (arrows), its solid 
component, and the mass effect on adjacent structures. 
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